Bull
$16.82
Precio del escenario
$10.540
-0.060 (-0.57%)Al cierre
Crescent Capital BDC, Inc. is a specialty finance company focused on lending to middle-market companies. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It invests primarily in secured debt, including first lien, unitranche first lien and second-lien debt, and unsecured debt, including mezzanine and subordinated debt, as well as related equity securities of private United States middle-market companies. It is focused on purchasing interests in loans or making debt investments, either directly from its target companies as primary market or private credit investments (private credit transactions), or primary or secondary market bank loans or high-yield transactions in the syndicated market (syndicated loans and bonds). Although its focus is on investing in less liquid private credit transactions. The Company is managed by Crescent Cap Advisors, LLC.
Crescent Capital BDC Inc (CCAP) is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $10.54, which is significantly below the average price target of $12.50 set by analysts. The company has reported a net income loss of $15.5 million in Q1 2026 and $3.25 million in Q2 2026, indicating ongoing financial struggles. Additionally, the RSI is at 26.53, suggesting that the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity. The main risk is the significant drop in net asset value per share, which decreased to $17.82, marking the eighth consecutive quarterly decline, primarily due to unrealized losses on investments. Overall, the combination of poor earnings, a high forward P/E of 55.56, and a recent dividend cut of 19% makes CCAP a sell for long-term investors.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Crescent Capital Reports Q2 2026 Earnings Decline

Crescent BDC Reports Q2 2026 Financial Results with Dividend Declarations

Crescent BDC Announces Q2 Financial Results Release Date

Insider Buying Analysis at Crescent Capital BDC and EquipmentShare

Oppenheimer Downgrades Crescent Capital to Perform Amid Fee Reductions
Crescent Capital BDC, Inc. is a specialty finance company focused on lending to middle-market companies. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It invests primarily in secured debt, including first lien, unitranche first lien and second-lien debt, and unsecured debt, including mezzanine and subordinated debt, as well as related equity securities of private United States middle-market companies. It is focused on purchasing interests in loans or making debt investments, either directly from its target companies as primary market or private credit investments (private credit transactions), or primary or secondary market bank loans or high-yield transactions in the syndicated market (syndicated loans and bonds). Although its focus is on investing in less liquid private credit transactions. The Company is managed by Crescent Cap Advisors, LLC. It operates in the Financials sector.
Crescent Capital BDC Inc (CCAP) is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $10.54, which is significantly below the average price target of $12.50 set by analysts. The company has reported a net income loss of $15.5 million in Q1 2026 and $3.25 million in Q2 2026, indicating ongoing financial struggles. Additionally, the RSI is at 26.53, suggesting that the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity. The main risk is the significant drop in net asset value per share, which decreased to $17.82, marking the eighth consecutive quarterly decline, primarily due to unrealized losses on investments. Overall, the combination of poor earnings, a high forward P/E of 55.56, and a recent dividend cut of 19% makes CCAP a sell for long-term investors.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.